1989 About 30 young scientists and technologists from the field of Microbiology, Immunology, Biotechnology, Biochemistry, Pharmaceutical Sciences and Biochemical Engineering were recruited by DBT and trained in the field of vaccine production and quality control in reputed institutes in India and a specialized training at the Institute of Poliomyelitis and Viral Encephalitis, Moscow, Russia

1994 BIBCOL went public and the shares of the company were listed in Delhi, Mumbai and Kanpur stock exchanges

1996 The company started formulating OPV from bulk since January 1996

1999 The company acquired WHO-GMP certification

2000 BIBCOL bagged an order from UNICEF as well as from Ministry of Health and Family Welfare, Govt.of India for a total of 170 million doses

2001 The company bagged another larger order of 270 million doses from UNICEF as well as from the Ministry of Health & Family Welfare, Govt.of India

2004 Due to the extensive restructuring with in the company, BIBCOL achieved a turn over of Rs.53.25 crores during the fiscal year 2004-2005 and has earned a net profit of 132.44 lacs for the first time against the loss pf Rs.3.14 crore during the previous fiscal year 2003-2004

2005 For the first time, the company has signed a MoU with DBT for the fiscal year 2005-2006. The OPV plant at Chola, Bulandshahr has supplied about 1016 million doses of OPV to the National Immunization Program so far. During the year 2004-2005, 120 million doses were formulated and supplied to NIP, capturing nearly 60 percent of the total market share of polio vaccines in the country.

2006 The company has secured a place among the Top 20 Biotech companies in the country through its commendable performance.